Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes.

Afsaneh Fendereski Ebrahim Hajizadeh Shahpar Haghighat Aliakbar Rasekhi

Published in: BMC women's health (2022)

Our results confirm that the most prevalent breast cancer was HR+/HER2- tumor type which had the best prognosis. It is also concluded that HR-/HER2+ patients had the worst outcomes, with the highest rates of recurrence and metastasis and the lowest overall and disease-free survival rates.

Keyphrases

end stage renal disease
free survival
ejection fraction
newly diagnosed
chronic kidney disease
metastatic breast cancer
peritoneal dialysis
prognostic factors
type diabetes
metabolic syndrome
patient reported outcomes
adipose tissue
weight loss